Comparison · NCT02157935-d82e4298
Symbicort pMDI vs Formoterol Turbuhaler: Number of Patients With Moderate or Severe COPD Exacerbation.
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Symbicort pMDI vs Formoterol Turbuhaler: Number of Patients With Moderate or Severe COPD Exacerbation. Trial comparisons, record NCT02157935-d82e4298. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02157935-d82e4298
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.282 | 0.248 | 0.319 | wilson | |
| Risk in group 2 | 0.333 | 0.297 | 0.371 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0506 | -0.102 | 0.00121 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.848 | 0.716 | 1 | log | |
| Odds ratio, group 1 over group 2 | 0.788 | 0.618 | 1.01 | log | |
| Number needed to treat, for one fewer participant with the outcome on Symbicort pMDI than on Formoterol Turbuhaler | 19.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Symbicort pMDI | Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation | 171 | 606 | OG000 |
| Group 2 | Formoterol Turbuhaler | Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation | 204 | 613 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Patients With Moderate or Severe COPD Exacerbation.
- Description
The number of patients who developed moderate or severe COPD exacerbation during treatment period were reported. Cox proportional hazards regression model was fitted to data to compare the two treatment arms .~The hazard ratio and 95% CI were estimated.
- Time frame
- From randomzation to EoT W 26
- Population
Source ClinicalTrials.gov
Trial
- Title
- Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease
- NCT number
- NCT02157935
- Phases
- PHASE3
- Conditions
- COPD Patients
- Interventions
- Symbicort, Formoterol turbohaler, Placebo for Symbicort pMDI, Placebo for Formoterol Turbohaler
- Lead sponsor
- AstraZeneca
- Results first posted
- 2017-06-12
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02157935?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02157935-d82e4298